Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should minimal residual disease negativity not be the end point of myeloma therapy?

Literature DB >> 29296971

Should minimal residual disease negativity not be the end point of myeloma therapy?

Abstract

Publisher's Note: This article has a companion Point by Anderson. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Entities: Disease

Year: 2017 PMID： 29296971 PMCID： PMC5728450 DOI： 10.1182/bloodadvances.2017000109

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

22 in total

1. Minimal residual disease in multiple myeloma.

Authors: Nikhil C Munshi; Kenneth C Anderson
Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544

Review 2. Multiple myeloma.

Authors: Antonio Palumbo; Kenneth Anderson
Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245

3. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors: Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal: N Engl J Med Date: 2015-06-02 Impact factor: 91.245

4. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Authors: Ola Landgren; Nicole Gormley; Danielle Turley; Roger G Owen; Andy Rawstron; Bruno Paiva; David Barnett; Maria Arroz; Paul Wallace; Brian Durie; Constance Yuan; Ahmet Dogan; Maryalice Stetler-Stevenson; Gerald E Marti
Journal: Am J Hematol Date: 2014-12 Impact factor: 10.047

5. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Authors: Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau
Journal: N Engl J Med Date: 2016-10-06 Impact factor: 91.245

6. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors: Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal: Blood Date: 2011-11-29 Impact factor: 22.113

7. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Authors: Elena Zamagni; Cristina Nanni; Katia Mancuso; Paola Tacchetti; Annalisa Pezzi; Lucia Pantani; Beatrice Zannetti; Ilaria Rambaldi; Annamaria Brioli; Serena Rocchi; Carolina Terragna; Marina Martello; Giulia Marzocchi; Enrica Borsi; Ilaria Rizzello; Stefano Fanti; Michele Cavo
Journal: Clin Cancer Res Date: 2015-06-15 Impact factor: 12.531

8. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors: Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal: N Engl J Med Date: 2015-08-26 Impact factor: 91.245

Review 9. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316

10. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors: Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal: JAMA Oncol Date: 2017-01-01 Impact factor: 31.777

3 in total

Review 1. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Authors: Hannah A Blair
Journal: Drugs Date: 2017-12 Impact factor: 9.546

2. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors: Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal: Bone Marrow Transplant Date: 2020-01-28 Impact factor: 5.483

Review 3. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors: Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal: Front Oncol Date: 2019-08-20 Impact factor: 6.244

3 in total